Chen Zheling, Ge Minyao
Department of Traditional Chinese Medicine, Zhenxin Community Health Service Center, Shanghai 201824, P.R. China.
Department of Urology Surgery, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, P.R. China.
Exp Ther Med. 2021 Mar;21(3):242. doi: 10.3892/etm.2021.9673. Epub 2021 Jan 22.
Benign prostate hyperplasia (BPH) is one of the well-known urological neoplasms common in males with an increasing number of associated deaths in aging males. It causes uncomfortable urinary symptoms, including urine flow blockage, and may cause bladder, urinary tract or kidney problems. The histopathological and clinical knowledge regarding BPH is limited. In the present study, an approach was applied that uses genome-scale microarray expression data to discover a wide range of protein-protein interactions in addition to focusing on specific genes responsible for BPH to develop prognostic biomarkers. Various genes that were differentially expressed in BPH were identified. Gene and functional annotation clusters were determined and an interaction analysis with disease phenotypes of BPH was performed, as well as an RNA tissue specificity analysis. Furthermore, a molecular docking study of certain short-listed gene biomarkers, namely anterior gradient 2 (AGR2; PDB ID: 2LNT), steroid 5α-reductase 2 (PDB ID: 6OQX), zinc finger protein 3 (PDB ID: 5T00) and collagen type XII α1 chain (PDB ID: 1U5M), was performed in order to identify alternative Chinese herbal agents for the treatment of BPH. Data from the present study revealed that AGR2 receptor (PDB ID: 2LNT) and berberine (Huang Bo) form the most stable complex and therefore may be assessed in further pharmacological studies for the treatment of BPH.
良性前列腺增生（BPH）是男性常见的著名泌尿系统肿瘤之一，在老年男性中相关死亡人数不断增加。它会引起不适的泌尿系统症状，包括尿流阻塞，并可能导致膀胱、尿路或肾脏问题。关于BPH的组织病理学和临床知识有限。在本研究中，采用了一种方法，利用基因组规模的微阵列表达数据来发现广泛的蛋白质-蛋白质相互作用，同时关注负责BPH的特定基因以开发预后生物标志物。鉴定了在BPH中差异表达的各种基因。确定了基因和功能注释簇，并对BPH的疾病表型进行了相互作用分析以及RNA组织特异性分析。此外，对某些入围的基因生物标志物进行了分子对接研究，即前梯度2（AGR2；PDB ID：2LNT）、类固醇5α-还原酶2（PDB ID：6OQX）、锌指蛋白3（PDB ID：5T00）和十二型胶原α1链（PDB ID：1U5M），以确定治疗BPH的替代中草药制剂。本研究的数据显示，AGR2受体（PDB ID：2LNT）和黄连素（黄柏）形成了最稳定的复合物，因此可在进一步的药理学研究中评估其对BPH的治疗作用。
